Your take wasn't spot on. It still isn't spot on. The past 3 sessions have shown increased trading volume that dwarfs anything trickled in by TheraCour. Also, even though there were no sales for a month, the price continued to slide sideways with a downward bias, that after 2 months of increasing valuation against even heavier insider sales. The weakness was at least as much a result of delayed reporting and a dearth of material events. I was very surprised that attempts to take the price back down to the 40 to 60 cent level were met with buying and continued support, then it as in spite of TheraCour sales. What we have here is the cusp of significant news events. Increased buying now well above last month's recommended buying top of 90 cents points to that.
Market Data 
Markets 
AI
